Multiple sclerosis (MS) is a chronic immunemediated disease that potentially requires
symptomatic and disease-modifying therapies. Numerous symptoms (eg, fatigue, spasticity …

Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally
considered to be an inflammatory, autoimmune, demyelinating disease of the central …

The treatment of multiple sclerosis (MS) falls into 3 categories: treatment of exacerbations,
slowing disease progression with disease-modifying therapies (DMTs), and symptomatic …

Multiple sclerosis (MS) is a presumed autoimmune disorder of the central nervous system,
resulting in inflammatory demyelination and axonal and neuronal injury. New diagnostic …

Currently, several disease-modifying therapies for the treatment of multiple sclerosis are
established and more are likely to be introduced. These treatment options differ with respect …

Since 1993, six disease-modifying therapies for multiple sclerosis (MS) have been proven to
be of benefit in rigorous phase III clinical trials. Other agents are also available and are used …

Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous
system (CNS). It predominantly affects young women and is one of the most common causes …

Although there has been unequivocal progress in the development of treatments for multiple
sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

PURPOSE OF REVIEW Newly introduced disease-modifying therapies offer greater efficacy
than previous therapies but also have serious side effects. This article reviews factors useful …